



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:52
Last Report Issued 12/12/2017 09:20

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1267SP
Patient ID 1267SP
Chain 17002218
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 17002218
Received 12/12/2017 07:18

Sample ID 17002218-001
Matrix Serum or Plasma
Patient Name 1267SP
Patient ID 1267SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

1267SP Clobazam, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Clobazam	None Detected	ng/mL	20	
----------	---------------	-------	----	--

Synonym(s): Urbanyl®; Frisium®

Following a single 20 mg oral dose, the mean peak plasma concentration: 465 ng/mL (range, 220 - 710 ng/mL) after 1.7 hours.

Following a single 40 mg oral dose, the mean peak plasma concentration: 730 ng/mL at 2.5 hours. The plasma concentration decreased to 360 ng/mL at 12 hours, 180 ng/mL at 48 hours and 17 ng/mL at 96 hours.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.